Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Akorn Inc.
WARNING LETTER
•Akorn Inc.•August 30, 2018

Akorn Inc. – FDA Warning Letter, Aug 30, 2018

Record Details

The FDA issued a Warning Letter to Akorn, Inc. following an inspection of their Somerset, New Jersey drug manufacturing facility from July 23 to August 30, 2018. The letter identifies significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals, rendering their drug products adulterated.

Key violations include: 1. **Inadequate Investigations (21 CFR 211.192):** The firm failed to thoroughly investigate out-of-specification (OOS) laboratory results and manufacturing deviations. Examples cited include an OOS osmolality result for ketorolac tromethamine ophthalmic solution with observed product defects (low volume, leakage, residue), and metal shavings found on aseptic filling equipment for lidocaine hydrochloride 2% jelly. Laboratory investigations into "trial" injections and OOS impurity results for azelastine hydrochloride and ciprofloxacin ophthalmic solutions were also deemed inadequate, with many remaining open for extended periods. 2. **Inadequate Computer System Controls and Data Integrity (21 CFR 211.68(b), 21 CFR 211.194(a)):** Data could be deleted and altered from laboratory instruments, and standalone instruments were not backed up. A database, usage logs, and audit trails were deleted from a particle counter. Numerous sample injection sequences lacked required signatures for review, and chemists had full administrator access to instrument computers, allowing data

Company
Akorn Inc.
Inspection date
August 30, 2018
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations I
Person
  • Craig W. Swanson (Deputy District Director)
View Company Profile

ID · b6bc2de9-3951-4ca6-a801-032f0bfaf5b0

Violation Codes8
21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 CFR 211.19221 CFR 211.68(b)21 CFR 211.194(a)21 CFR 211.113(b)21 CFR 211.188

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Akorn Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.